A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00747734

Enrollment

Registered

2008-09-05

Start date

2008-09-30

Completion date

Unknown

Last updated

2011-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Cancers

Keywords

Neuropilin-1, NRP1, anti-NRP1, anti-angiogenic

Brief summary

This is a Phase I, first-in-human, open-label, dose-escalation study of MNRP1685A administered by IV infusion every 3 weeks in patients with locally advanced or metastatic solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable. This study will be conducted at up to three study centers in the United States.

Interventions

DRUGMNRP1685A

Escalating intravenous dose

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years * Incurable, locally advanced, or metastatic solid malignancy that has progressed on, or failed to respond to, at least one prior regimen * Evaluable or measurable disease per RECIST (in certain circumstances, prostate or ovarian cancer patients with non-measurable disease)

Exclusion criteria

* Inadequate hematologic or organ function * Anti-cancer therapy within 4 weeks prior to initiation of study treatment * Recent history of or current clinically significant gastrointestinal, cardiovascular or pulmonary disorders * Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or thrombolytics, or a filter of the inferior vena cava * Active infection or autoimmune disease * Known human immunodeficiency virus (HIV) infection * Pregnancy or breast feeding

Design outcomes

Primary

Measure	Time frame
Incidence and nature of dose-limiting toxicities (DLTs)	Length of study

Secondary

Measure	Time frame
Total exposure (AUC)	Length of study
Maximum and minimum serum concentrations	Length of study
Clearance	Length of study
Volume of distribution	Length of study

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026